FMP

FMP

Enter

IGM Biosciences, Inc. (NASDAQ:IGMS) Earnings Report Analysis

- (Last modified: Nov 11, 2024 8:18 AM)

twitterlinkedinfacebook
blog post cover photo

Image credit: Google Images

  • IGM Biosciences, Inc. (NASDAQ:IGMS) is set to release its quarterly earnings with an anticipated EPS of -$0.80 and projected revenue of $270,000.
  • The company reported a larger-than-expected loss in the previous quarter but showed slight improvement year-over-year.
  • Despite negative earnings, IGMS's financial ratios indicate strong liquidity and a relatively low level of debt.

IGM Biosciences, Inc. (NASDAQ:IGMS) is a biotechnology company focused on developing innovative therapies for cancer and autoimmune diseases. The company is currently conducting trials for Imvotamab, a promising treatment for conditions like rheumatoid arthritis and systemic lupus erythematosus. Despite its potential, IGMS faces financial challenges, as reflected in its upcoming earnings report.

IGMS is set to release its quarterly earnings on November 11, 2024, with Wall Street estimating an earnings per share (EPS) of -$0.80 and projected revenue of $270,000. In the previous quarter, IGMS reported a larger-than-expected loss of $1.01 per share, surpassing the Zacks Consensus Estimate of a $0.82 loss. However, this was a slight improvement from the $1.04 loss per share in the same quarter last year.

Despite the negative earnings, IGMS exceeded revenue expectations in the third quarter of 2024. The company has a negative price-to-earnings (P/E) ratio of -3.57, indicating it is not currently profitable. The high price-to-sales ratio of 265.52 suggests that the stock is trading at a significant premium relative to its sales, reflecting investor optimism about its future prospects.

IGMS's financial metrics highlight its challenges. The enterprise value to sales ratio is 255.94, and the enterprise value to operating cash flow ratio is negative at -4.44, indicating difficulties in generating positive cash flow. The earnings yield is -27.99%, further emphasizing the lack of profitability. However, the debt-to-equity ratio of 0.32 shows a relatively low level of debt, and a current ratio of 7.06 suggests strong liquidity, enabling IGMS to cover short-term liabilities effectively.

Other Blogs

May 14, 2024 11:41 AM - Sanzhi Kobzhan

The easiest way to calculate stock’s target price and why the target price is important.

A stock's target price, also known as its fair value, is an indication of what a share can cost based on the company’s forecasted financial statements. It is important to know a stock's fair value to find undervalued stocks with great growth potential. Let's consider how investment analysts calculat...

blog post title

May 24, 2024 9:30 AM - Rajnish Katharotiya

How to Access and Analyze Earnings Call Transcripts

Earnings call transcripts are invaluable resources for investors, analysts, and financial enthusiasts. They provide insights into a company's performance, strategy, and future outlook, making them essential for making informed investment decisions. With Financial Modeling Prep, Earnings Call Transcr...

blog post title

May 27, 2024 3:30 PM - Rajnish Katharotiya

The best 5 GPU stocks other than NVDA

In the ever-evolving world of technology, certain sectors have consistently demonstrated exceptional growth and innovation. The graphics processing units (GPUs) industry is one such sector, offering investors a golden opportunity for potentially high returns. In this blog, we'll delve into why inves...

blog post title
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep